CRIPTO and cancer: We predicted the binding site in the CRIPTO CFC domain responsible for the interaction with specific residues of GRP78 SBDβ which can be targeted both by inhibitors in future work to prevent this interaction leading to stopping the pathway responsible for cancer resistance to chemotherapy.